MAP3K7 and ovarian carcinoma: One study examined the efficacy of a metabolic inhibitor cocktail containing transforming growth factor beta-activated kinase 1 (TAK1) (AMPK activator) and FASN synthase inhibitors against ovarian cancer cells [97].